The law has been passed, but legally the final word has not yet been spoken. Resistance is forming on three levels against the removal of cannabis flowers from insurance reimbursement: rapid interim legal protection before the social courts, potential constitutional challenge, and a previously overlooked data protection gap. We outline where the law is vulnerable and what evidence supports these claims.
📑 Inhaltsverzeichnis
With the GKV Contribution Rate Stabilization Act, which the Bundestag passed on July 10, 2026, approximately 65,000 insured patients will lose reimbursement for dried cannabis flowers, according to publicly reported estimates. The flowers are completely removed from the catalog of benefits under § 31 Abs. 6 SGB V; they remain prescribable and available through pharmacies, but fundamentally no longer covered by statutory health insurance. Additionally, the remaining cannabis medications—namely standardized extracts, dronabinol, and nabilone—will only be reimbursable after a six-month trial with an approved finished pharmaceutical product. We have already described the affected patients‘ perspective in detail. The legislature justifies the change by citing stabilization of insurance contributions and controlling pharmaceutical expenditures. This article examines the legal side: how can the law actually be challenged?
The Quick Lever: Interim Legal Protection at the Social Court
The most direct path does not lead through Karlsruhe, but through the social courts. Anyone who has an existing, indefinite cost coverage authorization under § 31 Abs. 6 SGB V can attempt to secure it provisionally by way of a preliminary injunction under § 86b Abs. 2 of the Social Court Act (SGG). Such an interim application requires two things: an entitlement to the injunction, meaning a plausible substantive claim for benefits, and grounds for urgency, meaning particular immediacy. This urgency typically exists when waiting until the main proceeding is decided would lead to severe, barely reversible disadvantages. An imminent abrupt discontinuation of an ongoing, medically supervised therapy can constitute such a disadvantage.
This is precisely the lever being used in the first known case. An affected patient, Marguerite Arnold, has informed the editorial team that she has filed an interim application with the Social Court Frankfurt am Main against her health insurance fund after it failed to respond to her request for confirmation of continued treatment. The application document available to us is deliberately narrowly drafted: it does not ask the court to decide on the constitutionality of the law, but merely to maintain her already-approved treatment until clarification in a separately announced main proceeding. A receipt confirmation from the Social Court Frankfurt am Main dated July 27, 2026, confirms that the application was personally submitted there; it is available to the editorial team. According to the applicant, a court file number has not yet been assigned but is expected in the coming week. According to her account, there is no transition period until the law takes effect, which means she currently faces potential loss of coverage in approximately three weeks.
For the outcome of such proceedings, it is crucial how courts weigh urgency and prospects of success on the merits. Mere delay is insufficient; the threatened disadvantage must be credibly demonstrated. Established patients with long-standing, documented approval likely have the strongest arguments here.
The Big Question: Estoppel and Equal Treatment
Behind interim legal protection lies the actual constitutional dispute, which would be fought out in the main proceeding. At its core is the question of estoppel: Can existing, indefinitely granted authorizations be effectively devalued by a change in law, and if so, under what conditions? The Federal Constitutional Court distinguishes between true and false retroactivity and weighs the trust of those affected against the legislature’s objectives. With ongoing continuous treatments, this balancing is not trivial.
A second point of attack is the equality principle from Article 3 of the Basic Law. Since flowers remain available through private prescription, merely no longer reimbursed, a distinction based on ability to pay emerges: those who can afford it continue their therapy, while those who cannot are directed to alternative preparations. Whether this differentiation is materially justified will be a central point of contention. The statutory situation is documented; the constitutional assessment, however, remains open and will be decided by courts, not by the parties to the proceedings.
Beyond individual lawsuits, an organized legal approach is now forming. The Working Group Cannabis as Medicine (ACM) has announced that, together with lawyer and professor Oliver Tolmein, it is preparing legal steps against the new regulation, including interim applications and a constitutional complaint. The ACM estimates the number of affected patients at approximately 65,000 and attributes the reimbursement exclusion to a recommendation from the former chair of the Federal Joint Committee, who had demanded six-month priority for finished pharmaceutical products. Should a constitutional complaint actually be filed, the question of estoppel and equal treatment would no longer be debated only in individual cases, but as a matter of principle.
The Unexpected Point of Attack: Data Protection
Less obvious, but legally noteworthy, is a third approach that focuses on data protection. The mandated six-month therapy trial creates a process in which it must be documented that a finished pharmaceutical product proved unsuccessful before extracts or dronabinol can be reimbursed. This generates processing of sensitive health data within the meaning of Article 9 of the General Data Protection Regulation (GDPR), which requires a special legal basis under Article 9 Abs. 2.
The decisive question is: who is actually the controller in the data protection sense, what data is collected for what purpose, and to whom is it transmitted to assess the reimbursement claim? The law does not appear to answer this explicitly. Marguerite Arnold, who raises these questions, also sees pharmacies being pushed into an undefined role in data review and states she has filed a complaint with the Federal Commissioner for Data Protection and Freedom of Information (BfDI). The complaint available to us makes no finished accusations but deliberately poses questions about responsibility, legal basis, and purpose limitation.
However, this premise requires nuance. The processing of health data in pharmacies does not occur in a legal vacuum but within an established framework: Article 9 Abs. 2 letter h of the GDPR permits processing of such data within the context of healthcare provision, § 300 SGB V regulates the settlement of pharmacies with health insurance funds and the data transmitted thereby, and § 203 StGB subjects pharmacists to a duty of confidentiality. Pharmacies undertake defined formal and pharmaceutical reviews, such as verifying the validity of a prescription, but do not review the medical diagnosis; this remains within the therapeutic authority of the physician. The actual open question is therefore less whether any framework exists at all than how the concrete documentation of the six-month therapy trial fits into that framework, and here the central role lies with the prescribing physician. The data protection vulnerability via the pharmacy role is thus disputed; its final assessment rests with the supervisory authorities.
That the priority regulation raises questions as a matter of craftsmanship is not a minority opinion: the Pharmaceutical Times called it a „foreign body in the cost-cutting law.“ Whether this results in a fundamental data protection defect does not follow from that; assessing that is a matter for the supervisory authorities.
Whether the GKV flowers cutoff survives in court will be decided on three questions: urgency, estoppel, and who is responsible for the therapy trial data.
The applicant in her own words. Marguerite Arnold, who identified herself to the editorial team as an affected patient, describes her goal as follows: the interim application should secure uninterrupted cost coverage until the main case is decided. According to her, she will file this later this week and will expressly request referral to the Federal Constitutional Court. For her, it is not just about her own case but also about „thousands of other patients who cannot easily fight this through.“ Additionally, she announces plans to submit a data protection complaint to the European Commission.
What This Means for Patients
For those affected, it is important to assess the situation soberly. A single interim application initially affects only the individual person; it does not overturn the law. Fundamental clarification could only come through a main proceeding and, ultimately, the Federal Constitutional Court, and such proceedings take time. Until then, flowers remain available through private prescription, though at personal expense. Organizations like the German Hemp Association and the Federal Association of Cannabis Patients are mobilizing in parallel at the political level against the regulation.
Whether the outlined points of attack will succeed is open. What is clear is that the deletion of flower reimbursement is not legally unassailable but raises permissible questions at several points. We will continue to monitor the proceedings and report as soon as substantive evidence, such as case numbers or decisions, becomes available.
Sollten Cannabisblüten weiterhin von den Kassen erstattet werden?
Note: This article reports on ongoing legal proceedings. Statements by individual parties are marked as such and are not independently verifiable by us in every respect. This text does not constitute legal advice.
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
